| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2023 ( Subtotal = $0 ) |
| | 2023 | 2021 | OPIANT PHARMACEUTICALS, INC. | 233 WILSHIRE BLVD STE 280 | SANTA MONICA | CA | 90401-1240 | LOS ANGELES | USA | U01DA046093 | Development of an intranasal, long duration opioid antagonist to treat opioid overdose | 000 | 3 | NIH | 5/15/2023 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $1,800,581 ) |
| | 2021 | 2021 | OPIANT PHARMACEUTICALS, INC. | 233 WILSHIRE BLVD STE 280 | SANTA MONICA | CA | 90401-1240 | LOS ANGELES | USA | U01DA046093 | Development of an intranasal, long duration opioid antagonist to treat opioid overdose | 000 | 3 | NIH | 3/26/2021 | $1,800,581 |
|
| Issue Date FY: 2020 ( Subtotal = $0 ) |
| | 2020 | 2019 | OPIANT PHARMACEUTICALS, INC. | 233 WILSHIRE BLVD STE 280 | SANTA MONICA | CA | 90401-1240 | LOS ANGELES | USA | U01DA046093 | Development of an intranasal, long duration opioid antagonist to treat opioid overdose | 002 | 2 | NIH | 9/3/2020 | $0 |
| | 2020 | 2019 | OPIANT PHARMACEUTICALS, INC. | 201 SANTA MONICA BLVD FL 5 STE 500 | SANTA MONICA | CA | 90401-2213 | LOS ANGELES | USA | U01DA046093 | Development of an intranasal, long duration opioid antagonist to treat opioid overdose | 001 | 2 | NIH | 2/26/2020 | $0 |
| | 2020 | 2019 | OPIANT PHARMACEUTICALS, INC. | 201 SANTA MONICA BLVD FL 5 STE 500 | SANTA MONICA | CA | 90401-2213 | LOS ANGELES | USA | U01DA046093 | Development of an intranasal, long duration opioid antagonist to treat opioid overdose | 000 | 2 | NIH | 11/21/2019 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $3,035,646 ) |
| | 2019 | 2019 | OPIANT PHARMACEUTICALS, INC. | 201 SANTA MONICA BLVD STE 500 | SANTA MONICA | CA | 90401-2213 | LOS ANGELES | USA | U01DA046093 | Development of an intranasal, long duration opioid antagonist to treat opioid overdose | 000 | 2 | NIH | 3/27/2019 | $3,035,646 |
|
| Issue Date FY: 2018 ( Subtotal = $2,551,346 ) |
| | 2018 | 2018 | OPIANT PHARMACEUTICALS, INC. | 201 SANTA MONICA BLVD STE 500 | SANTA MONICA | CA | 90401-2213 | LOS ANGELES | USA | U01DA046093 | Development of an intranasal, long duration opioid antagonist to treat opioid overdose | 001 | 1 | NIH | 9/20/2018 | -$2,551,346 |
| | 2018 | 2018 | OPIANT PHARMACEUTICALS, INC. | 201 SANTA MONICA BLVD STE 500 | SANTA MONICA | CA | 90401-2213 | LOS ANGELES | USA | U01DA046093 | Development of an intranasal, long duration opioid antagonist to treat opioid overdose | 000 | 1 | NIH | 4/17/2018 | $2,551,346 |
| | 2018 | 2018 | OPIANT PHARMACEUTICALS, INC. | 201 SANTA MONICA BLVD STE 500 | SANTA MONICA | CA | 90401-2213 | LOS ANGELES | USA | U01DA046093 | Development of an intranasal, long duration opioid antagonist to treat opioid overdose | 001 | 1 | NIH | 9/20/2018 | $2,551,346 |
|
|
